The $1.4 Trillion Cardiovascular Disease Crisis: Why Revolutionary Blood Purification Could Transform Treatment Access
-
最新报道：Cardiovascular disease remains the world's leading cause of death, claiming over 17.9 million lives annually. Sigyn Therapeutics plans to enter the multi-billion dollar CVD treatment market with its innovative blood purification therapy, Sigyn Therapy™, targeting high-risk dialysis-dependent patients. The therapy aims to reduce lipoprotein(a), LDL-C, endotoxin, and inflammatory cytokines during routine dialysis, leveraging existing U.S. clinic infrastructure. Major players like Fresenius and DaVita dominate the $34 billion dialysis industry, where extending patient lifespans could significantly boost revenues. Sigyn's clinical feasibility study represents a potential paradigm shift in cardiovascular and renal care.
下一篇
Corporate Governance Gets a Social Media Makeover
- Nestlé terminated CEO Laurent Freixe without severance after he engaged in a romantic rela...
24小时热点
热点专题
418154